Information  X 
Enter a valid email address

VASTox plc (SUMM)

  Print      Mail a friend

Wednesday 04 April, 2007

VASTox plc

Additional Listing

VASTox plc
04 April 2007

                                   VASTox plc

                          ('VASTox' or 'the Company')



                          Additional Listing of Shares



Oxford, UK, 4 April 2007 - VASTox plc (AIM: VOX) notes that application has been
made for 158,546 ordinary shares of 10p each in the Company ('Ordinary Shares')
to be admitted to trading on the London Stock Exchange's AIM market for listed
securities ('Admission').



The new Ordinary Shares are being issued pursuant to the exercise of options.
Admission is expected to become effective on 12 April 2007.



                                    - ends -



For more information, please contact:


VASTox

Steven Lee, PhD, Chief Executive Officer              Tel: +44 (0)1235 443951
Darren Millington, Chief Financial Officer


Citigate Dewe Rogerson
Mark Swallow / David Dible / Valerie Auffray          Tel: +44 (0)207 638 9571



About VASTox plc



VASTox is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced chemistry and drug screening (chemical genomics)
technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.



VASTox has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.



VASTox's in-house drug development capabilities combine world-class expertise in
both medicinal and carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and cost of drug discovery and development by delivering data
that are highly predictive of the efficacy and toxicity of potential drug
compounds in humans.



The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: VOX



Further information about the company is available at www.vastox.com






                      This information is provided by RNS
            The company news service from the London Stock Exchange